MedTrace Logo

Convalescent Plasma for Treating Patients With COVID-19 Pneumonia Without Indication of Ventilatory Support

NCT04528368 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-08-06

No results posted yet for this study

Summary

The COVID-19 pandemic has been spreading continuously, and in Brazil, until August 18, 2020, there have been more than 3,359,000 cases with more than 108,536 deaths, with daily increases. The present study proposes to evaluate the efficacy and safety of using convalescent plasma for treating patients with COVID-19 pneumonia without indication of ventilatory support.

Conditions

Interventions

BIOLOGICAL

Convalescent plasma

The intervention group will receive 400 mL of convalescent plasma with a SARS-CoV-2 antispike antibody titer with a dilution ≥ 1: 320.

Sponsors & Collaborators

  • Hospital do Coracao

    collaborator OTHER

  • D'Or Institute for Research and Education

    lead OTHER

Principal Investigators

  • Eduardo M Rego, MD, PhD · D'Or Institute for Research and Education

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-11
Primary Completion
2021-12-30
Completion
2022-01-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04528368 on ClinicalTrials.gov